ArticleDiabetes, obesity & metabolism2022

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.

Thomas S J Crabtree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.